We would like to congratulate Lamb et al for the production of such a comprehensive guideline for the management of inflammatory bowel disease (IBD).1 Further clarification is warranted regarding screening for hepatitis B virus (HBV) prior to immunosuppression and subsequent management to reduce the risk of virus reactivation. The guidelines recommend screening for HBV at diagnosis and before immunomodulatory/biologic therapies. We strongly recommend that screening includes hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc) and antibody to hepatitis B surface antigen (anti-HBs) as outlined in the European Crohn’s and Colitis Organisation Opportunistic Infections Consensus.2 Lamb et al advise seeking specialist input prior to commencing immune-modifying therapy for those patients with active HBV (i.e. HBsAg positive). In line with national and international guidelines, …

中文翻译：

---

乙型肝炎再激活：降低炎症性肠病患者的风险

我们要祝贺 Lamb 等人制定了如此全面的炎症性肠病 (IBD) 管理指南。 1 关于在免疫抑制和后续管理之前筛查乙型肝炎病毒 (HBV) 以减少病毒再激活的风险。该指南建议在诊断时和免疫调节/生物治疗之前筛查 HBV。我们强烈建议筛查包括乙型肝炎表面抗原 (HBsAg)、乙型肝炎核心抗原抗体 (anti-HBc) 和乙型肝炎表面抗原抗体 (anti-HBs)，如欧洲克罗恩病和结肠炎组织机会性感染共识中所述。 2 Lamb 等人建议在对那些活动性 HBV 患者（即 HBsAg 阳性）。根据国家和国际准则，……